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Abstract
Background: Clinical scores to determine early (6-month) antiretroviral therapy (ART) mortality risk have not been
developed for sub-Saharan Africa (SSA), home to 70% of people living with HIV. In the absence of validated scores,
WHO eligibility criteria (EC) for ART care intensification are CD4 < 200/μL or WHO stage III/IV.
Methods: We used Botswana XPRES trial data for adult ART enrollees to develop CD4-independent and CD4-
dependent multivariable prognostic models for 6-month mortality. Scores were derived by rescaling coefficients.
Scores were developed using the first 50% of XPRES ART enrollees, and their accuracy validated internally and
externally using South African TB Fast Track (TBFT) trial data. Predictive accuracy was compared between scores and
WHO EC.
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Results: Among 5553 XPRES enrollees, 2838 were included in the derivation dataset; 68% were female and 83 (3%)
died by 6 months. Among 1077 TBFT ART enrollees, 55% were female and 6% died by 6 months. Factors predictive
of 6-month mortality in the derivation dataset at p < 0.01 and selected for the CD4-independent score included
male gender (2 points), ≥ 1 WHO tuberculosis symptom (2 points), WHO stage III/IV (2 points), severe anemia
(hemoglobin < 8 g/dL) (3 points), and temperature > 37.5 °C (2 points). The same variables plus CD4 < 200/μL (1
point) were included in the CD4-dependent score. Among XPRES enrollees, a CD4-independent score of ≥ 4 would
provide 86% sensitivity and 66% specificity, whereas WHO EC would provide 83% sensitivity and 58% specificity. If
WHO stage alone was used, sensitivity was 48% and specificity 89%. Among TBFT enrollees, the CD4-independent
score of ≥ 4 would provide 95% sensitivity and 27% specificity, whereas WHO EC would provide 100% sensitivity
but 0% specificity. Accuracy was similar between CD4-independent and CD4-dependent scores. Categorizing CD4-
independent scores into low (< 4), moderate (4–6), and high risk (≥ 7) gave 6-month mortality of 1%, 4%, and 17%
for XPRES and 1%, 5%, and 30% for TBFT enrollees.
Conclusions: Sensitivity of the CD4-independent score was nearly twice that of WHO stage in predicting 6-month
mortality and could be used in settings lacking CD4 testing to inform ART care intensification. The CD4-dependent
score improved specificity versus WHO EC. Both scores should be considered for scale-up in SSA.
Keywords: HIV, Acquired immuno-deficiency syndrome, Antiretroviral therapy, Mortality, Predictive models, Clinical
scores
Background
Over the last 16 years, the scale-up of HIV treatment
globally has reached over 24.5 million people living with
HIV (PLHIV) with lifesaving antiretroviral therapy
(ART), resulting in declines in both HIV-associated mor-
tality and HIV incidence [1–3]. However, each year there
are still about 770,000 global AIDS-related deaths, with
470,000 (61%) of these deaths occurring in sub-Saharan
Africa (SSA) [1]. To reduce AIDS-related mortality, the
global community is striving to reach 2030 targets of en-
suring at least 90% of PLHIV are on ART [4], which will
require ART enrollment for an additional 10 million of
the 37.9 million PLHIV globally, about two-thirds of
whom live in sub-Saharan Africa (SSA) [1]. Mortality
rates during ART are highest in the first 6 months of
therapy, and these early ART mortality rates continue to
be highest in SSA [5, 6]. If 2030 goals of reducing AIDS-
related mortality by 90% compared with 2010 are to be
met, substantial progress needs to be made in addressing
early ART mortality in SSA [5, 6], where 20–40% of new
ART enrollees still initiate ART with relatively advanced
HIV disease [7, 8].
To achieve these mortality reductions, efficient use of
available resources through differentiated service delivery
(DSD) models to provide tailored, patient-centered care
will be needed [9, 10]. The World Health Organization
(WHO) currently recommends intensification of care for
persons > 5 years old starting ART with advanced HIV
disease as defined by CD4+ T cell (CD4) count < 200 cells/
μL or WHO stage III/IV [8]. The intensification of care
package, which has been shown to reduce early mortality
[11], includes cotrimoxazole prophylaxis, tuberculosis
(TB) screening with subsequent TB treatment or TB
preventive therapy, cryptococcal antigen (CrAg) screening
with pre-emptive therapy for eligible CrAg-positive
people, and enhanced adherence counseling. However, the
majority of health facilities providing ART in low- and
middle-income countries (LMIC) lack access to rapid or
point-of-care (POC) CD4 testing [8]. In these settings, up
to half of adults with a CD4 count < 100/μL could be cate-
gorized as WHO stage I/II and would be missed by an ad-
vanced disease screening algorithm that relied on WHO
stage alone [11]. In addition, a screening tool for advanced
disease that relies only on CD4 count and WHO disease
stage misses the many other demographic and clinical pre-
dictors associated with early ART mortality [9]. To date,
most analyses evaluating eligibility for DSD models have
focused on identifying stable patients for de-escalation of
care [9]. Only one analysis from Haiti has evaluated a clin-
ical score for determining who needs intensification of
early ART care, and this was not externally validated [12].
Therefore, we evaluated whether a clinical score de-
rived from easily available covariates at ART initiation in
resource-constrained clinic settings could better predict
who is at risk for early (6-month) ART mortality than
the current WHO advanced disease eligibility criteria.
We developed clinical scores to help predict early ART
mortality risk for two scenarios: (1) a scenario where on-
site/rapid off-site CD4 testing is not available as is the
case for the majority of ART clinics in LMIC and (2) a
scenario where on-site/rapid off-site CD4 testing is
available.
Methods
We used data from the Xpert Package Rollout Evalu-
ation using a Stepped-wedge design (XPRES) trial to
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derive the two clinical scores to help clinicians identify
those at the highest risk of early ART mortality and
therefore in need of ART care intensification [13]. The
first clinical score assumes CD4 is unavailable at ART
initiation (i.e., a CD4-independent score) and the second
clinical score assumes CD4 count is available (i.e., a
CD4-dependent score). We used the first 50% of XPRES
cohort enrollees to derive a prediction model, and the
second 50% to internally validate the model. We then
used data from the TB Fast Track (TBFT) trial in South
Africa (SA) to externally validate the derived clinical
scores [14]. We compared the screening accuracy of our
derived clinical scores with existing CD4-based WHO
eligibility criteria for advanced disease and ART care
intensification.
XPRES study design and participants for prediction tool
development
XPRES was a multi-center, stepped-wedge cluster ran-
domized trial with a retrospective baseline component
conducted at 22 health facilities, including five hospitals
and 17 clinics, that were purposively selected to be rep-
resentative of HIV treatment clinics in Botswana [13]. In
the prospective, stepped-wedge portion of the trial, all
non-incarcerated, consenting, ART-naïve, HIV-positive
persons, regardless of TB treatment or symptom status,
presenting to the study clinics between August 2012 and
end of March 2014, were eligible for enrollment. Only
adolescents and adults (aged ≥ 12 years old) were in-
cluded in this analysis.
XPRES procedures
Per Botswana national guidelines during the time period
of the study, all XPRES study participants were eligible
for ART initiation if they had a CD4 count ≤ 350 cells/
μL, were diagnosed as having WHO stage III/IV events,
or were pregnant or breastfeeding [15]. All study partici-
pants received clinical care and follow-up appointments
per Ministry of Health (MOH) guidelines (see Add-
itional file 1, a table summarizing standard clinical care
follow-up).
Interventions
The prospective XPRES cohort was recruited within two
phases of the stepped-wedge trial. In the first phase, all
prospective XPRES participants received two enhanced
care interventions in addition to standard of care: (1)
additional support for intensified TB case finding and
(2) intensified tracing for patients missing clinic appoint-
ments. In the second phase, the Xpert® MTB/RIF assay
(Cepheid; Sunnyvale, CA) (Xpert) was initiated in place
of sputum smear microscopy for TB diagnosis. Details of
these interventions have been previously published [16]
and are provided in a supplementary appendix (see
Additional file 2, text describing enrollment and en-
hanced care interventions). We have previously shown
that there was no significant difference in 6-month ART
mortality between the two prospective phases of XPRES
[16]. Enrollment and follow-up procedures are described
in the supplementary appendix (see Additional file 2,
text). XPRES participants were followed for 12 months,
or until the end of TB treatment, whichever was later.
The final follow-up visits for XPRES enrollees were in
June 2015.
Development and temporal validation of the prediction
model
A clinically useful prediction model should demonstrate
accurate prediction of the outcome in data other than
that in which the model was developed. Therefore, we
split the XPRES dataset in a 1:1 ratio using the mid-
point of enrollment at each of the 22 study clinics to
create the derivation dataset (the first 50% of enrollees)
and the temporal validation dataset (the second 50% of
enrollees) [17].
Outcome
The outcome of interest for both the XPRES trial and
this analysis was early (6-month) ART mortality. We im-
plemented intensive efforts to ascertain true mortality
outcomes among participants, with deaths and date of
death either passively reported to the clinic by friends or
relatives or actively ascertained if the client had missed
an appointment or was considered lost to follow-up
(LTFU) (> 60 days late for a scheduled appointment)
[18]. Initial efforts to ascertain outcomes of clients who
missed an appointment by ≥ 1 day included up to five
phone calls to the client or contact and up to two home
visits. In addition, for all clients unreachable by phone
or home visit who met the LTFU definition, vital status
was ascertained through national Death Registry review.
By law, since 1969, all deaths need to be registered in
the Death Registry, which is maintained by the Botswana
Civil and National Registration Office. Available data
shows Death Registry data completeness to be high [16].
Candidate predictor variables
We selected candidate predictor variables for potential
inclusion in the predictive model based on prior publica-
tions, and the need for variables to be reproducible, ob-
jective, and readily available in resource-constrained
clinic settings [19]. We considered variables known to
be associated with mortality including age, sex (coded as
male, pregnant female, and non-pregnant female [20]),
education level, employment status, smoking history,
prior TB treatment, number of WHO TB symptoms,
weight, body mass index (BMI) (weight/height2),
hemoglobin level, CD4 count, temperature at ART
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initiation in degrees Celsius, and respiratory rate at ART
initiation [20–23].
Within the derivation dataset, we performed univari-
able analyses assessing the association of each variable
with risk of mortality using logistic regression. Because
follow-up of all XPRES and TBFT enrollees was
complete with true ascertainment of 6-month mortality
outcomes, 6-month risk was preferred to rate [16]. Con-
tinuous variables were assessed for non-linearity with
log odds of death using fractional polynomials, as well as
by comparing Akaike’s Information Criteria and Bayes-
ian Information Criteria between models with linear or
fractional polynomial terms. Where non-linearity was
observed, the appropriate fractional polynomial terms
were included in the logistic regression. We also exam-
ined scatter plots of linear and transformed continuous
variables and risk of mortality to assess inflection points
which might inform appropriate categorization of con-
tinuous variables.
For the multivariable analysis, a complete case ana-
lysis, whereby observations with missing data for key
variables were dropped, was chosen because few data
(< 10%) were missing. To generate a parsimonious
multivariable model, we used a stepwise backward
elimination approach, starting with all candidate vari-
ables and excluding variables sequentially if p > 0.01
using both automatic and manual approaches. We
also explored how findings changed using a forward
stepwise addition approach. Where two or more pre-
dictors were highly correlated, only one was selected,
to simplify the prognostic model. We created two
multivariable models: one in which CD4 was purpose-
fully excluded and one in which CD4 count was in-
cluded as a candidate variable to reflect situations
where CD4 is either unavailable or available at the
clinic. Plausible interactions between covariates (e.g.,
between CD4 and age) were assessed using the likeli-
hood ratio test.
In both the derivation and temporal validation
datasets, we assessed multivariable model calibration
(i.e., the agreement between probability of 6-month
mortality predicted by the model and observed prob-
ability of death within quantiles of predicted risk)
graphically in a calibration plot [17] and statistically
using the Hosmer-Lemeshow test. We also assessed
discrimination, the ability of our model to differenti-
ate patients who died by 6 months of ART vs. those
who did not, using the area under the receiver-
operating characteristic (AUROC) curve, also re-
ferred to as the C-statistic or C-index. AUROC
values of 0.7 to 0.79, 0.8 to 0.89, and ≥ 0.9 are re-
spectively considered acceptable, excellent, and out-
standing discrimination [24].
Two final multivariable models were used to generate
the two clinical scores (i.e., the CD4-independent and
CD4-dependent scores). For these models, continuous
variables were categorized in a clinically meaningful
manner based on their functional form and information
from the published literature. Each beta coefficient from
this logistic regression model was then rescaled to gen-
erate a clinical score by dividing each coefficient by the
smallest positive model coefficient and rounding to the
nearest integer. The total number of points was summed
for each participant to calculate their total clinical score.
External validation of risk scores
To externally validate the clinical risk score, we used
data collected independently from the TBFT trial from
Fig. 1 Study profile
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SA [14]. TBFT was an open-label cluster randomized
controlled trial, recruiting individuals from 24 primary
healthcare clinics in SA. All outpatient, HIV-positive
adults (aged ≥ 18 years) with CD4 counts < 150/μL, no
TB treatment in the past 3 months, and no ART in the
last 6 months were eligible. In the intervention clinics,
participants were classified by a study algorithm as hav-
ing high, medium, or low TB risk. High TB risk patients
Table 1 Comparison of characteristics of antiretroviral therapy enrollees between internal derivation, internal validation, and external
validation datasets
Internal derivation
dataset (N = 2838)
Internal validation
dataset (N = 2715)
External validation dataset
(TB Fast Track, SA; N = 1077)a
Demographics n Median or % n Median or % n Median or %
Age, years, median (IQR) 2838 33.8 (28.6–40.9) 2715 34.0 (28.6–41.4) 1077 38.0 (32.0–44.0)
Female, n, % 1938 68% 1779 66% 590 55%
If female, pregnant, n, % 520 27% 551 31% 0 0%
Marital status, n, % Married/civil union 300 11% 265 10%
Single 2441 86% 2346 86%
Widowed/divorced 97 3% 104 4%
Smoking history (ever smoked), n, % 517 18% 551 20% 238 22%
Currently employed, n, % 1270 45% 1286 47%
Education, n, % None 196 7% 200 7%
Primary 687 24% 596 22%
Secondary 1734 61% 1641 60%
Higher 221 8% 278 10%
HIV/TB history
Previous TB treatment, n, % Yes 277 10% 262 10%
WHO TB symptoms, n, %
Cough Yes 495 17% 547 20% 463 43%
Weight loss Yes 599 21% 555 20% 797 74%
Fever Yes 259 9% 245 9% 314 29%
Night sweats Yes 273 10% 253 9% 348 32%
Number of WHO TB symptoms, n, % 0 1975 70% 1911 70% 230 21%
1 427 15% 349 13% 285 26%
2 202 7% 216 8% 226 21%
3 141 5% 137 5% 178 17%
4 93 3% 102 4% 158 15%
Clinical characteristics
WHO stage III/IV, n, % 354 12% 307 11%
CD4 (cells/μL) Median (IQR) 2838 245 (143–315) 2715 240 (134–319) 1077 72 (36–110)
Weight (kilograms) Median (IQR) 2838 58.8 (51.8–68.2) 2715 59.7 (52.8–69.0) 1077 57.9 (50.8–67.0)
BMI (weight/height²) Median (IQR) 2838 21.5 (18.9–24.9) 2715 21.6 (19.1–25.0) 1077 21.3 (18.8–25.0)
Hemoglobin (g/dL) Median (IQR) 2838 11.9 (10.4–13.2) 2715 12.0 (10.7–13.4) 1077 11.3 (9.7–13.0)
Temperature (degrees Celsius) Median (IQR) 2838 36.2 (35.8–36.5) 2715 36.2 (35.8–36.6) 1077 36.4 (36.0–36.7)
Respiratory rate (breaths/min) Median (IQR) 2838 19 (18–20) 2715 19 (18–20)
Heart rate (beats/min) Median (IQR) 2838 84 (75–94) 2715 84 (75–95)
Mortality within 6months
Cumulative incidence, n, % 83 2.9% 67 2.5% 60 6%
Time to death (days) Median (IQR) 83 50 (25–105) 67 46 (16–87) 60 55 (30–112)
Abbreviations: IQR interquartile range, TB tuberculosis, WHO World Health Organization, CD4 CD4+ T cell count, TB tuberculosis, BMI body mass index, SA
South Africa
aTBFT study enrollees in the intervention arm who started ART
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(i.e., those with positive lateral flow urine lipoarabino-
mannan assay [LF-LAM], BMI < 18.5, or hemoglobin <
10 g/dL) started TB treatment immediately followed by
ART 2 weeks later. Medium TB risk participants (i.e.,
those with ≥ 1 WHO TB symptom only) were recom-
mended to have symptom-guided TB investigation. Low
TB risk patients (no TB symptoms or high-risk cri-
teria) were recommended to start ART immediately.
The primary outcome was all-cause mortality at 6
months after enrollment. We restricted this analysis
to intervention arm participants, for whom key vari-
ables such as temperature at enrollment were avail-
able, and to those patients who started ART, since
the outcome of interest was mortality within the first
6 months of ART. The median time from trial enroll-
ment to ART start in the intervention arm was 21
days. Participants were enrolled in TBFT between De-
cember 19, 2012, and December 18, 2014. The clin-
ical risk score for mortality was calculated by
assigning the same “points” to variables as for the
derivation cohort.
For both the XPRES cohort (combined derivation and
validation datasets), and the TBFT datasets, we explored
how sensitivity, specificity, positive predictive value
(PPV), negative predictive value (NPV), and AUROC
curve values varied with increasing clinical score in
terms of predicting 6-month mortality and compared
this screening accuracy and discrimination performance
with the WHO eligibility criteria for advanced disease.
Three risk groups were created to visualize increasing 6-
month ART mortality risk with increasing clinical score,
and the percentage of ART enrollees falling into each
risk group. Kaplan-Meier (K-M) curves were used to
visualize rates of early mortality within the three risk
groups.
All analyses were conducted using STATA 16 (Stata-
Corp, 2009, Stata Statistical Software, Release 16, College
Station, TX). The study is reported in concordance with
TRIPOD guidance for multivariable prediction models
(see Additional file 3, a table with the TRIPOD
checklist).
Results
From the XPRES cohort, 5553 eligible ART enrollees
with complete data for candidate predictors were in-
cluded in the analysis (Fig. 1). Overall, 150 (3%) of 5553
ART enrollees died within 6 months of ART initiation.
Fig. 2 Model A (excluding CD4) development and performance in the internal derivation and validation datasets respectively
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Internal derivation and temporal validation datasets
From the XPRES cohort, the internal derivation (N =
2838) and temporal validation (N = 2715) datasets were
created (Table 1). Key characteristics including median
age (34), percentage female (66–68%), median CD4
(240–245/μL), and 6-month mortality (2.5–2.9%) were
similar between internal XPRES derivation and valid-
ation datasets (Table 1). Notable differences between the
XPRES cohorts and TBFT external validation cohort
were that the TBFT cohort had a higher prevalence of
markers of advanced disease, with a higher prevalence of
≥ 1 TB symptom (79% versus 30%), lower median CD4
count (72 versus 240–245/μL), and higher incidence of
all-cause 6-month ART mortality (6.0% versus 2.5–2.9%)
(Table 1).
Development of the regression model
Table 2 summarizes the results of univariable and multi-
variable logistic regression model development. Al-
though the linear continuous variables of age, weight,
BMI, heart rate, and respiratory rate, as well as history
of smoking, were associated with 6-month mortality in
univariable analysis, these variables were either dropped
as candidate variables due to correlation (i.e., weight and
heart rate were dropped due to correlation with BMI
and temperature respectively) or eliminated in the step-
wise backward elimination approach due to p values in
multivariable analysis > 0.01.
The final multivariable model A (which simulated the
situation where CD4 is unavailable) included sex, num-
ber of WHO TB symptoms, WHO disease stage,
hemoglobin concentration (continuous, linear term), and
temperature (modeled as two transformed terms follow-
ing output from the multivariable fractional polynomial
analysis) (Table 2). In the final multivariable model B
(which simulated the situation where CD4 is available),
the same variables included in model A plus CD4 were
included (Table 2).
Internal validation of final regression models
The Hosmer-Lemeshow statistics for model A (exclud-
ing CD4) on both the derivation (p = 0.381) and valid-
ation (p = 0.210) datasets indicated good model fit (see
Additional file 4, table showing results of Hosmer-
Lemeshow tests). Similarly, the calibration curves (Fig. 2)
indicate adequate prediction performance for the 10 risk
groups in terms of the predicted number of deaths
Fig. 3 Model B (including CD4) development and performance in the internal derivation and validation datasets respectively
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within 6 months of ART versus the observed number of
deaths. In addition, the AUROC curve values for the
derivation (0.874) and validation (0.822) datasets indi-
cated excellent discrimination (Fig. 2).
The Hosmer-Lemeshow statistics for model B (includ-
ing CD4) on both the derivation (p = 0.735) and valid-
ation (p = 0.677) datasets also indicated good model fit
(see Additional file 4, table showing results of Hosmer-
Table 3 Multivariable model and clinical score generation from the derivation dataset (N = 2838)
Predictor—model A (excluding CD4) Predictor—model B (including CD4)
AOR 95% CI p
value
ß
coefficient
Score AOR 95% CI p
value
ß
coefficient
Score
Sex and pregnancy status Female (pregnant) 1.00 – – – 0 1.00 – – – 0
Female (non-
pregnant)
1.94 (0.58–6.50) 0.283 0.66 1 1.71 (0.53–5.52) 0.373 0.53 1
Male 3.54 (0.95–
13.26)
0.060 1.26 2 2.93 (0.82–
10.44)
0.097 1.08 2
Number of WHO TB
symptoms
0 1.00 – – – 0 1.00 – – – 0
≥ 1 3.65 (2.24–5.97) <
0.001
1.30 2 3.33 (2.06–5.38) < 0.001 1.20 2
WHO stage I/II 1.00 – – – 0 1.00 – – – 0
III/IV 2.72 (1.42–5.20) 0.003 1.00 2 2.55 (1.32–4.92) 0.005 0.94 2
Temperature at enrollment ≤ 37.5 °C 1.00 – – – 0 1.00 – – – 0
> 37.5 °C 3.39 (1.65–6.96) 0.001 1.22 2 3.37 (1.56–7.26) 0.002 1.21 2
CD4 count ≥ 200/μL – – – – N/A 1.00 – – – 0
< 200/μL – – – – N/A 2.05 (1.20–3.50) 0.009 0.72 1
Anemia statusa No anemia 1.00 – – – 0 1.00 – – – 0
Mild/moderate
anemia
5.03 (2.57–9.87) <
0.001
1.62 2 4.58 (2.37–8.84) < 0.001 1.52 3
Severe anemia 9.42 (3.43–
25.89)
<
0.001
2.24 3 8.02 (3.04–
21.14)
< 0.001 2.08 4
Abbreviations: AOR adjusted odds ratio, CI confidence interval, WHO World Health Organization
aAnemia severity was classified according to World Health Organization criteria as follows: no anemia, hemoglobin level of ≥ 13.0 g/dL for men, ≥ 12.0 g/dL for
non-pregnant females, and ≥ 11.0 g/dL for pregnant females; mild/moderate anemia, 8.0 to < 13.0 g/dL for men, 8.0 to < 12.0 g/dL for non-pregnant women, and
7.0 to < 11.0 g/dL for pregnant women; and severe anemia, < 8.0 g/dL for males and non-pregnant females and < 7.0 g/dL for pregnant women
Fig. 4 CD4-independent and CD4-dependent clinical score cards
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Lemeshow tests), with calibration curves (Fig. 3) indicat-
ing adequate prediction performance for the 10 risk
groups. However, in the highest risk group (risk group
10), model B overestimated mortality risk in the valid-
ation dataset, with 48 deaths predicted but only 34 ob-
served (see Additional file 4, table showing results of
Hosmer-Lemeshow tests). In addition, the AUROC
curve values for the derivation (0.887) and validation
datasets (0.836) indicated excellent discrimination
(Fig. 3).
Transformation from the regression model to clinical
score
We used WHO advanced disease classifications for
WHO stage (stage III or IV), and CD4 count (< 200
cells/μL). Anemia severity in adults was classified ac-
cording to WHO criteria as follows [25]: no anemia was
defined as hemoglobin ≥ 13.0 g/dL for men, ≥ 12.0 g/dL
for non-pregnant females, and ≥ 11.0 g/dL for pregnant
females; mild/moderate anemia was defined as 8.0 to <
13.0 g/dL for men, 8.0 to < 12.0 g/dL for non-pregnant
Fig. 5 Sensitivity, specificity, PPV, and NPV of clinical score in predicting 6-month mortality in XPRES dataset (N = 5553) and external validation TB
Fast Track Dataset (N = 1077) for models A (excluding CD4) and B (including CD4)
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females, and 7.0 to < 11.0 g/dL for pregnant females; and
severe anemia was defined as < 8.0 g/dL for males and
non-pregnant females and < 7.0 g/dL for pregnant fe-
males. Temperature was classified as ≤ 37.5 °C versus >
37.5 °C based on the observed distribution of mortality
risk as measured temperature increased (see Add-
itional file 5, figure of association between temperature
and risk of death), and a common definition of a low-
grade fever or higher (> 37.5 °C) [26]. The multivariable
model with categorization of these continuous variables
in the derivation dataset is presented in Table 3. Because
heart rate might be more easily available in LMIC set-
tings than temperature, we also created an alternate clin-
ical score where heart rate replaced temperature (see
Additional file 6, table showing alternate clinical score).
In this alternate score, we used heart rate cut-offs of >
120 versus ≤ 120 beats/minute, which were informed by
both prior published literature [22, 27] and observed in-
flection points in the association between heart rate and
risk of death (see Additional file 5, figure of association
between heart rate and risk of death).
Model A, categorized in this way, retained statistically
excellent discrimination in both derivation (AUROC
0.867) and validation datasets (AUROC 0.818), and the
Hosmer-Lemeshow statistic p values were 0.269 in the
derivation and 0.334 in the validation datasets indicating
good calibration. Similarly, model B AUROC statistics
were 0.874 in the derivation and 0.830 in the validation
datasets, with Hosmer-Lemeshow statistic p values of
0.367 and 0.307 in the derivation and validation datasets,
respectively, indicating good model fit. The clinical
scores that could be used in clinic settings to identify
those at risk of early 6-month mortality, depending on
the availability of CD4 count, are illustrated in Fig. 4.
External validation of risk scores
The clinical score for each predictor was generated, and
the possible range for the total score was 0 to 11 for
model A and 0 to 13 for model B (see Additional file 7,
tables showing performance of clinical scores). Figure 5
shows the performance of the two clinical scores at dif-
ferent cut-offs, in terms of sensitivity, specificity, nega-
tive predictive value (NPV), positive predictive value
(PPV), and percentage of enrollees screened into ART
care intensification.
For the CD4-independent clinical score derived
from model A, (Fig. 5) among XPRES enrollees, a
clinical score of ≥ 4 would screen in 36% of ART
enrollees into a care intensification pathway, provid-
ing 86% sensitivity and 66% specificity in detecting
those at risk for early mortality, whereas the WHO
advanced disease eligibility criteria (CD4 < 200/μL or
WHO stage III/IV) would screen in 44% of ART
enrollees, providing 83% sensitivity and 58%
specificity. Notably, if the WHO advanced disease eli-
gibility criterion of WHO stage III/IV only was used
since CD4 is unavailable, 12% of ART enrollees would
be screened into an ART care intensification pathway,
with only 48% sensitivity in detecting 6-month mor-
tality and 89% specificity. All 72 XPRES patients with
WHO stage III/IV who died by 6 months of ART
would also be screened into intensification of care
pathways using a clinical score cut-off of ≥ 4. Among
TBFT enrollees, the clinical score of ≥ 4 would screen
in 74% of ART enrollees, providing 95% sensitivity
and 27% specificity in detecting early mortality, versus
the WHO advanced disease eligibility criteria which
would screen in 100% of ART enrollees, with 100%
sensitivity but 0% specificity.
For the CD4-dependent clinical score derived from
model B, a clinical score of ≥ 5 would screen in 38% of
ART enrollees into a care intensification pathway, pro-
viding 92% sensitivity and 63% specificity in detecting
those at risk for early mortality. Ninety-seven percent
(121 of 125) XPRES patients with either a CD4 < 200/μL
or WHO stage III/IV who died by 6 months would be
screened into intensification of care pathways using a
clinical score ≥ 5. Among TBFT enrollees, the clinical
score of ≥ 5 would screen in 81% of ART enrollees, pro-
viding 88% sensitivity and 20% specificity in detecting
early mortality. For both CD4-dependent and CD4-
independent clinical scores, screening accuracy charac-
teristics were very similar when heart rate replaced
temperature in the clinical score (see Additional file 8,
figure of screening accuracy for the alternate clinical
scores).
The AUROC for CD4-independent (0.845) and CD4-
dependent (0.852) clinical scores remained high for
XPRES enrollees but was low for TB FT enrollees (0.568
for CD4-independent and 0.569 for CD4-dependent
scores) (see Additional file 9, figure of AUROC for clin-
ical score performance).
For the CD4-independent clinical score, risk scores
were grouped into low- (< 4), moderate- (4–6), and
high-risk categories (≥ 7) (Fig. 6), with 6-month low-,
moderate-, and high-risk group incidence percentages
being 1%, 4%, and 17% among XPRES enrollees and
1%, 5%, and 30% among TBFT enrollees. Similarly,
for the CD4-dependent clinical score, risk scores were
grouped into low- (< 5), moderate- (5–8), and high-
risk categories (≥ 9) (Fig. 6), with 6-month low-, mod-
erate-, and high-risk group mortality percentages be-
ing 0%, 4%, and 18% for XPRES enrollees and 3%,
5%, and 16% for TBFT enrollees. Figure 7 shows K-M
failure curves of mortality over the first 6 months of
ART according to the low-, moderate-, and high-risk
groups, indicating that specific populations of moder-
ately high- and high-risk groups, in high need of care
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intensification, were differentiated by the respective
clinical scores.
Discussion
To our knowledge, these are the first externally validated
clinical scores for ART care intensification generated for
SSA. The scores, which have superior screening accuracy
characteristics in predicting early mortality risk than
WHO-recommended advanced disease eligibility criteria,
are not dependent on CD4 testing access, can differenti-
ate mortality risk into three risk groups, could improve
access to evidence-based early ART care packages, im-
prove efficiency of advanced disease DSD models, and
facilitate improved differentiated care [9].
The CD4-independent clinical score, designed for set-
tings where CD4 is unavailable at ART intitiation, with a
cut-off score of ≥ 4 was largely as sensitive (86–95%) in
screening in persons at risk of death by 6 months as the
current WHO advanced disease eligibility criteria (83–
100%) and nearly twice as sensitive as WHO eligibility
criteria that would rely on WHO stage alone (48%).
Compared with the CD4-based WHO advanced disease
Fig. 6 Distribution of risk scores and 6-month mortality risk in the XPRES dataset (N = 5553) and external validation TB Fast Track Dataset (N = 1077) for
models A (excluding CD4) and B (including CD4)
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eligibility criteria, the CD4-independent clinical score
had higher specificity and would screen 8–26% fewer
ART enrollees into intensified care pathways, suggesting
the screening tool could also increase efficiency of in-
vestments in DSD models for advanced disease. There-
fore, in the many settings in SSA that lack access to
rapid CD4 testing, the CD4-independent clinical score
should be considered for scale-up to facilitate early ART
care intensification, with the potential for reductions in
early ART mortality [11]. In addition, in those settings
where CD4 is available, using the CD4-dependent clin-
ical score with a cut-off score of ≥ 5 could have similar
or increased sensitivity and superior specificity com-
pared with WHO advanced disease eligibility criteria,
with the potential to both reduce early ART mortality
and improve efficiency of DSD algorithms.
In contrast to current WHO guidelines, which rec-
ommend only the use of CD4 count and WHO HIV
disease staging to identify patients at high risk for
morbidity and mortality, our composite risk score
provides both more comprehensive and specific infor-
mation on the magnitude of risk for each patient by
integrating additional objective variables into the as-
sessment [9]. The additional variables included in our
score are both clinical and demographic. The clinical
variables of WHO TB symptom screen, temperature,
and anemia severity are known to be associated with
serious comorbidities that significantly increase early
Fig. 7 Survival curves stratified by risk scores in the XPRES dataset (N = 5553) and external validation TB Fast Track Dataset (N = 1077) for models
A (excluding CD4) and B (including CD4)
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mortality risk, while the demographic variable in the
scores (the gender variable of male, female non-
pregnant, and female pregnant) captures important
generalizable differences in early mortality risk in
SSA, which are due to both psychosocial and bio-
logical factors [28, 29]. Our risk scores are careful to
be simple (5 or 6 variables assessed), use objective co-
variates rather than variables that are more open to
interpretation, and use variables that should be avail-
able, or could easily be made available, at the POC in
LMIC. Our score could be relatively easily included
in paper medical records relevant for the first HIV
clinic or ART initiation visit and should not require a
calculator, unlike clinical scores developed for
resource-rich settings that require either electronic
medical record or website access to calculate the
score (e.g., the Veterans Aging Cohort Study (VACS)
or EuroSIDA scores) [30–32].
The hemoglobin concentration variable in our scores
is more available in LMIC than POC CD4 testing, al-
though scale-up of CD4 testing is needed and ongoing.
Notably, WHO has long designated hemoglobin testing
one of four essential laboratory services in SSA [33], and
hemoglobin tests are the most commonly performed la-
boratory test globally [34, 35]. For example, in Malawi,
one of the most resource-constrained countries in the
world which is ranked 172 out of 189 countries on the
human development index, hemoglobin testing through
point-of-care HemoCue® [34] or the WHO Hemoglobin
Color Scale is relatively widely available [35]. In the 2014
Malawi national health facility survey to assess access to
diagnostic tests, 82% of hospitals had access to
hemoglobin testing, with access only superseded by mal-
aria diagnostic testing (95%) and HIV diagnostic testing
(95%), whereas CD4 testing was only available in 43% of
hospitals [36]. Across all health facility types (hospitals,
health centers, clinics, and health posts), hemoglobin
testing was three times more widely available than CD4
testing [36], although there is a need for scale-up of
both tests. In addition to being currently more widely
accessible in SSA than CD4 testing, POC hemoglobin
testing is currently easier to scale up than CD4 test-
ing. Available POC hemoglobin measurement devices
tend to be durable, easy to use, and not reliant on
electricity supply, and require minimal training and
supervision [34] while also providing good accuracy
in LMIC [37, 38]. To date, these POC hemoglobin
devices have been less expensive than currently avail-
able POC CD4 systems and are useful for non-HIV-
related care (e.g., <$100/POC hemoglobin measure-
ment device and $0.12–0.75/test [34] vs. about $7430/
POC CD4 device and about $8.70/test [39]). Both
CD4 testing and hemoglobin testing are important at
the point of care, and less expensive POC CD4 lateral
flow assays and transcutaneous spectrophotometry so-
lutions for hemoglobin level measurement may be-
come available in the future [40–42].
Additional advantages of developing clinical scores
with a variety of cut-offs are that it allows program man-
agers to choose cut-offs with associated screening accur-
acy characteristics, allowing program managers to
choose cut-offs based on funding availability, by trading
sensitivity for improved specificity [9].
Another potential advantage of the combined clinical
score over the WHO advanced disease criteria is the
ability to differentiate three risk groups (low, moderate,
and high), with the highest risk group having 6-month
mortality rates of 16–30% versus 0–3% in the low and
4–5% in the moderate risk groups. While all patients
with moderate or high scores might benefit from stan-
dardized outpatient intensified early ART care, patients
in the highest risk group might be candidates for add-
itional interventions to help navigate the relatively com-
plex time of early ART. During this time, clinicians need
to rapidly search for, diagnose, or rule out comorbidities,
and both choose and time appropriate therapies, all
within the context of ART-driven immune reconstitu-
tion [43, 44]. Our clinical score could be used to inform
a clinical trial of such interventions.
Moderate to severe anemia was a stronger predictor
than CD4 count and overall was the strongest predictor
of early ART mortality in our cohort, similar to other
studies in SSA [21, 45, 46]. Anemia is the most com-
mon hematological complication of HIV disease among
PLHIV [47] and develops through several mechanisms
including direct HIV infection of hematopoietic pro-
genitor cells, dysregulated erythropoiesis through indir-
ect effects of proinflammatory cytokines, and through
anemia of chronic disorders (ACD), which is thought
to be the most common pathway [48]. ACD is driven
by hepatic expression of hepcidin, an acute phase
reactant that causes iron to be diverted from the circu-
lation and sequestered within cells of the reticuloendo-
thelial system through downregulation of ferroportin
channels [49]. TB also drives ACD through this
hepcidin-ferroportin interaction [49, 50]. In turn, se-
questration of iron inside macrophages and T cells
might support both intracellular mycobacterial growth
[46, 49] and HIV viral replication [51], showing the po-
tential for rapid worsening of HIV, TB, and severe
hepcidin-driven anemia. Therefore, although ART is
the most important treatment of HIV-associated
anemia, early treatment of any associated co-infections
is crucial [46]. In a separate analysis, we show that
moderate to severe anemia was also predictive of active
TB infection in the XPRES cohort, similar to other ana-
lyses [46]. Given the strong association between mod-
erate to severe anemia, early mortality, and active TB,
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which is the most common cause of early mortality in
SSA [52], the scores associated with observed
moderate-severe anemia in this analysis (2–4 points)
appropriately bring the total clinical score very close to
the threshold for ART care intensification. Per current
WHO guidelines, care intensification should include
further investigations for TB, especially disseminated
TB, through the use of the urine TB-LAM assay and
Xpert MTB/RIF [46, 50, 53, 54].
Another notable finding is that measured temperature
at > 37.5 °C at ART initiation was strongly predictive of
early ART mortality, independent of the WHO TB
symptom screen for fever or night sweats, which was
also predictive of mortality. This indicates the import-
ance of objective measures of fever in addition to patient
history [23]. In addition, our analysis shows that in those
settings where measured temperature measurement is
not available, measured heart rate (> 120 versus ≤ 120/
min) is a suitable replacement variable. Notably, some of
the key inflammatory cytokines that drive hepcidin re-
lease and fever are the same (e.g., interleukin (IL)-6,
tumor necrosis factor which stimulates IL-6 release, in-
terferons, and microbial-derived Toll-like receptors) and
are important for both pathways [49, 55]. Disseminated
undiagnosed TB or TB diagnosed late is the most com-
mon infectious cause of death among PLHIV in sub-
Saharan Africa, accounting for about 40% of deaths [52].
However, a recent autopsy study of causes of death
among new HIV clinic enrollees in SA found that 59%
of decedents had evidence of two or more concurrent
infections [56]. Most bacterial infections were due to
common pathogens, such as Klebsiella spp., Salmonella
spp., Haemophilus influenzae, and Staphylococcus aur-
eus, while cryptococcal infection was found in 13% [56].
Targeting an antimicrobial package of interventions to
patients who screen positive for our proposed clinical
scores, such as the package of interventions recom-
mended by WHO or trialed in the REALITY trial (con-
tinuous trimethoprim–sulfamethoxazole, ≥ 12 weeks of
isoniazid–pyridoxine (once active TB is ruled out), 12
weeks of fluconazole, 5 days of azithromycin, and a sin-
gle dose of albendazole), could significantly reduce mor-
tality for patients who screen positive [11].
The prognostic importance of male gender in predict-
ing mortality was correlated with older age and smoking
history in our model, and we chose to include the single
gender variable rather than two additional variables
(age ≥ 55 and smoking) in the CD4-dependent clinical
score to make the most parsimonious clinical score and
because male gender is a more generalizable predictor of
poor outcomes in SSA [29, 57, 58]. In addition, similar
to many ART programs in SSA [20, 59], pregnant
women in XPRES, who were (1) more likely to be diag-
nosed at an earlier disease stage through routine testing
at antenatal care and (2) able to initiate ART immedi-
ately once diagnosed unlike non-pregnant women diag-
nosed with HIV at the time [15], had lower mortality
than non-pregnant women starting ART in bivariate
analysis [20, 59]. However, if ART programs in SSA are
able in the future to achieve earlier testing and ART ini-
tiation for male and non-pregnant female PLHIV, it is
likely gender and pregnancy status could become less
important predictors, while predictors like smoking and
older age will become more important [57]. Although
smoking is not part of the clinical score, this article pro-
vides additional evidence for the need for tobacco smok-
ing reduction programs for PLHIV, separate or included
in early ART care intensification algorithms, to minimize
not only the risk of ischemic cardiovascular diseases but
also the risk of malignancies and bacterial infections, in-
cluding TB [60].
Strengths of this study include the use of data from
prospective cohorts nested within clinical trials, meaning
there was minimal missing covariate data and strong as-
certainment of the primary outcome of interest (6-
month ART mortality) (e.g., only one patient was LTFU
from the XPRES cohort and was excluded from this ana-
lysis [16]). Additional strengths include the relatively
high screening accuracy in both the XPRES and TBFT
cohorts, from two geographically separate cohorts, with
very different cohort characteristics (e.g., XPRES enrol-
lees represent general outpatient ART enrollees while
TBFT enrollees had homogenously low CD4 counts (<
150/μL)). Notably, discrimination, as measured by the
AUROC of the clinical scores, was lower in the TBFT
than in the XPRES cohort, but at the chosen clinical
score cut-offs, the clinical score still provided similar
sensitivity and superior specificity in predicting early
ART mortality compared with the WHO advanced dis-
ease eligibility criteria. The lower discriminatory capacity
of the clinical scores in the TBFT cohort is not surpris-
ing given the TBFT cohort reflects a relatively
homogenous ART population with advanced HIV dis-
ease. Notably, while in the XPRES cohort 6% of ART
enrollees were newly diagnosed and treated for TB, in
the TBFT cohort 62% were treated for TB through a
risk-based TB-treatment algorithm [14], suggesting that
the risk score is likely to be generalizable across a wide
range of new ART enrollee cohorts. However, additional
validation exercises are needed and planned to further
assess generalizability.
Limitations include that the risk score has not yet been
validated in a cohort enrolled under HIV test-and-treat
guidelines, something which is planned in the near fu-
ture. Other limitations include the fact that while the
gender and pregnancy variable is relevant in SSA and
many resource-limited settings, it is not generalizable to
cohorts in resource-rich settings like the USA and
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Europe, where males often have better outcomes than
female ART enrollees. Although the specificity of the
clinical scores is superior to the WHO advanced disease
eligibility criteria, a substantial percentage of ART enrol-
lees (36–38% in the XPRES cohort) would be screened
into receiving an advanced disease care package, which
would require a monitoring system to assess implemen-
tation fidelity. In addition, these screening tools were
validated in clinical trial cohorts that received relatively
intensive TB screening and treatment services, and
therefore, those that died did so despite access these ser-
vices. Finally, although the clinical score is highly sensi-
tive in screening in almost all patients with low CD4
count and advanced WHO disease stage at risk of death
into intensification of care pathways, and has superior or
similar sensitivity to current WHO advanced disease
screening criteria, it is possible for some patients with a
very low CD4 count and advanced WHO stage to have a
clinical score that falls below the specified cut-off, and
clinical discretion to screen these rare patients missed by
the screening tool into intensification of care pathways
is warranted.
Conclusions
In conclusion, where CD4 testing is not available in
similar LMIC, especially in SSA, the CD4-independent
risk score should be strongly considered for scale-up to
facilitate early ART care intensification, with the poten-
tial for significant reductions in early ART mortality if
targetted individuals are provided with evidence-based
care packages [11]. For clinics where CD4 count is avail-
able, the use of the CD4-dependent clinical score could
improve both sensitivity and specificity over WHO ad-
vanced disease eligibility criteria, with the potential to
reduce early ART mortality and improve efficiency of
DSD algorithms. Finally, further research to understand
best management of ART enrollees enrolled in the high-
est risk categories is warranted to further explore mor-
tality reduction interventions. Together, these actions
could help drive progress to AIDS 2030 goals of zero
AIDS deaths in the region of the world with the highest
HIV/AIDS-associated mortality.
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